Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90Y Epratuzumab Tetraxetan Following R-CHOP In Elderly DLBCL Patients

被引:1
|
作者
Kraeber-Bodere, Francoise [1 ]
Maisonneuve, Herve [2 ]
Lamy, Thierry [3 ]
Le Gouill, Steven [4 ]
Deconninck, Eric [5 ]
Pallardy, Amandine [1 ]
Bodet-Milin, Caroline [1 ]
Milpied, Noel [6 ]
Morineau, Nadine [7 ]
Foussard, Charles [8 ]
Gastinne, Thomas [4 ]
Gressin, Remy [9 ]
Toumilhac, Olivier [10 ]
Gyan, Emmanuel [11 ]
Moreau, Anne
Chauvet, Alain Faivre [1 ]
Cazeau, Anne-Laure [12 ]
Garin, Etienne
Vuillez, Jean-Philippe [13 ]
Chatal, Jean-Francois [14 ]
Harousseau, Jean-Luc [15 ]
Moreau, Philippe [4 ]
Wegener, William [16 ]
Goldenberg, David [17 ]
Soubeyran, Pierre [18 ]
机构
[1] CHU Nantes, Nucl Med Serv, F-44035 Nantes 01, France
[2] CH La Roche Yon, La Roche Sur Yon, France
[3] CHU Rennes, Hematol Dept, Rennes, France
[4] CHU Nantes, Hematol Dept, F-44035 Nantes 01, France
[5] Hop Jean Minjoz, F-25030 Besancon, France
[6] Hop Haut Leveque, Pessac, France
[7] Ctr Catherine Sienne, Nantes, France
[8] CHU Angers, Serv Malad Sang, Angers, France
[9] CHU Grenoble, INSERM, Inst Albert Bonniot, U823, F-38043 Grenoble, France
[10] CHU Clermont Ferrand, Serv Hematol Adultes & Therapie Cellulaire, Clermont Ferrand, France
[11] CHRU Tours, Serv Hematol & Therapie Cellulaire, Tours, France
[12] Inst Bergonie, Nucl Med Serv, Bordeaux, France
[13] CHU Michallon, Nucl Med Serv, Grenoble, France
[14] GIP ARRONAX, St Herblain, France
[15] Rene Gauducheau Canc Ctr, St Herblain, France
[16] Immunomed Inc, Clin Res, Morris Plains, NJ USA
[17] Ctr Mol Med & Immunol, Belleville, NJ USA
[18] Inst Bergonie, Bordeaux, France
关键词
D O I
10.1182/blood.V116.21.2875.2875
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:1184 / 1184
页数:1
相关论文
共 48 条
  • [1] Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90y-Epratuzumab Tetraxetan Following R-CHOP in Elderly DLBCL Patients: A Lysa Phase II Prospective Trial
    Kraeber-Bodere, Francoise
    Pallardy, Amandine
    Le Gouill, Steven
    Maisonneuve, Herve
    Lamy, Thierry
    Bouabdallah, Krimo
    Milpied, Noel
    Jardel, Henry
    Deconinck, Eric
    Morineau, Nadine
    Foussard, Charles
    Brion, Annie
    Gressin, Remy
    Tournilhac, Olivier
    Gyan, Emmanuel
    Moreau, Anne
    Berthou, Christian
    Dreyfus, Francois
    Bodet-Milin, Caroline
    Cazeau, Anne-Laure
    Garin, Etienne
    Vuillez, Jean-Philippe
    Campion, Loic
    Moreau, Philippe
    Wegener, William A.
    Goldenberg, David M.
    Soubeyran, Pierre
    BLOOD, 2012, 120 (21)
  • [2] Consolidation anti-CD22 fractionated radioimmunotherapy (RIT) with 90Y-epratuzumab tetraxetan following R-CHOP in elderly diffuse large B-cell lymphoma (DLBCL) patients
    Pallardy, Amandine
    Soubeyran, Pierre
    Le Gouill, Steven
    Bodet-Milin, Caroline
    Faivre-Chauvet, Alain
    Garin, Etienne
    Vuillez, Jean-Philippe
    Wegener, William
    Goldenberg, David
    Kraeber-Bodere, Francoise
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52
  • [3] Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial
    Kraeber-Bodere, Francoise
    Pallardy, Amandine
    Maisonneuve, Herve
    Campion, Loic
    Moreau, Anne
    Soubeyran, Isabelle
    Le Gouill, Steven
    Tournilhac, Olivier
    Daguindau, Etienne
    Jardel, Henry
    Morineau, Nadine
    Bouabdallah, Krimo
    Gyan, Emmanuel
    Moles, Marie-Pierre
    Gressin, Remy
    Berthou, Christian
    Sadot, Sophie
    Moreau, Philippe
    Deau, Benedicte
    Bodet-Milin, Caroline
    Cazeau, Anne-Laure
    Garin, Etienne
    Salaun, Pierre-Yves
    Vuillez, Jean-Philippe
    Gouilleux-Gruart, Valerie
    Barbet, Jacques
    Wegener, William A.
    Goldenberg, David M.
    Lamy, Thierry
    Soubeyran, Pierre
    LANCET HAEMATOLOGY, 2017, 4 (01): : E35 - E45
  • [4] Clinical update on fractionated radioimmunotherapy in patients with NHL using humanized 90Y labeled anti-CD22 epratuzumab
    Chatal, J
    Harousseau, J
    Griesinger, F
    Meller, J
    Pfreundschuh, M
    Kirsch, C
    Naumann, R
    Kropp, J
    Morschhauser, F
    Huglo, D
    ANNALS OF ONCOLOGY, 2005, 16 : 68 - 69
  • [5] Radioimmunotherapy in NHL at high cumulative doses of 90Y with fractionated doses of dota-conjugated, humanized anti-CD22 IGG, epratuzumab
    Morschhauser, F.
    Kraeber-Bodere, F.
    Huglo, D.
    Petillon, M.
    Chatal, J.
    Harousseau, J.
    Home, H.
    Teoh, N.
    Wegener, W. A.
    Goldenberg, D. M.
    ANNALS OF ONCOLOGY, 2008, 19 : 88 - 88
  • [6] Fractionated radioimmunotherapy in NHL with DOTA-conjugated, humanized anti-CD22 IgG, epratuzumab: Results at high cumulative doses of 90Y
    Kraeber-Bodere, F.
    Morschhauser, F.
    Huglo, D.
    Petillon, M.
    Chatal, J.
    Harousseau, J. L.
    Horne, H.
    Teoh, N.
    Wegener, W. A.
    Goldenberg, D. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] FDG-PET predicts response to fractionated radioimmunotherapy with 90Y-epratuzumab anti-CD22 MAB in patients with NHL.
    Bodet-Milin, C
    Rousseau, C
    Campion, L
    Ansquer, C
    Dupas, B
    Milpied, N
    Mahe, B
    Chatal, JF
    Wegener, WA
    Goldenberg, DM
    Kraeber-Bodere, F
    BLOOD, 2005, 106 (11) : 275B - 276B
  • [8] Final results of a Phase I/II trial of fractionated radioimmunotherapy (RAIT) with anti-CD22 90Y-epratuzumab tetraxetan in relapsed/refractory non-Hodgkin lymphoma (NHL)
    Goldenberg, D. M.
    Kraeber-Bodere, F.
    Morschhauser, F.
    Petillon, M.
    Huglo, D.
    Meller, J.
    Kirsch, C.
    Kropp, J.
    Le Gouil, S.
    Le Gouil, S.
    Bodet-Milin, C.
    Teoh, N.
    Chatal, J.
    Wegener, W. A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S237 - S237
  • [9] Fractionated radioimmunotherapy in NHL with dota-conjugated, humanized anti-CD22 epratuzumabat high cumulative 90Y doses
    Morschhauser, F.
    Kraeber-Bodere, F.
    Petillon, M.-O.
    Chatal, J.-F.
    Harousseau, J.-L.
    Horne, H.
    Teoh, N.
    Wegener, W. A.
    Goldenberg, D. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 151 - 151
  • [10] Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma
    Witzig, Thomas E.
    Tomblyn, Michael B.
    Misleh, Jamal G.
    Kio, Ebenezer A.
    Sharkey, Robert M.
    Wegener, William A.
    Goldenberg, David M.
    HAEMATOLOGICA, 2014, 99 (11) : 1738 - 1745